Trial Profile
A Randomized, Multicenter Open Label Phase II Trial of Paclitaxel + Ramucirumab Versus Paclitaxel Alone in Patients With Squamous-cell Carcinoma of the Esophagus, Refractory or Intolerant to Combination Therapy With Fluoropyrimidine and Platinum-based Drugs - The RAMOS STUDY
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Paclitaxel
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms RAMOS
- 24 Oct 2023 Results evaluating the safety and efficacy of Ram plus paclitaxel, presented at the 48th European Society for Medical Oncology Congress
- 06 Jun 2023 Final results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Status changed to discontinued due to slow accrual, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.